ClinicalTrials.gg
TerminatedNCT03310320DERMISUpdated Apr 25, 2019

Study to Determine if AZD0284 is Effective and Safe in Treating Plaque Psoriasis

A Phase 1 interventional study of AZD0284 oral solution 2.5 mg/mL and Placebo in Plaque Psoriasis Vulgaris, sponsored by AstraZeneca. Terminated at 4 sites in Denmark. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-04-25.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Why this study was terminated
The study is temporarily suspended due to preclinical findings that are currently under evaluation

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Psoriasis by AstraZeneca — none open to participants now, none under way, none of them phase 3. Psoriasis · AstraZeneca.

Started
2017
with 1 other
Phase 1
5 of 11
none open now
Registered
11th of 11
by date

Among the 11 studies in Psoriasis by AstraZeneca, this one is one of 2 that started in 2017, is one of 5 in phase 1, and was the 11th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

None of the 11 studies in Psoriasis by AstraZeneca is open now. The open studies under Psoriasis, anywhere →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Psoriasis by AstraZeneca as a file.
02

Study summary

The Sponsor is developing the study drug, AZD0284, for the potential treatment of Plaque psoriasis. Psoriasis is a skin condition that causes red, flaky, crusty patches of skin covered with silvery scales. The severity of the disease varies, but in many cases it can have a major impact on their quality of life if not adequately treated.

The purpose of the study is to determine the short term safety, pharmacodynamic and clinical effect of AZD0284 in patients with psoriasis.

Read the detailed description

This is a randomised, double-blind, placebo-controlled, multi-centre, parallel group Phase 1b study, designed to evaluate the pharmacodynamic effects, clinical efficacy and safety of AZD0284 compared with placebo as measured by the relative change from baseline in Psoriasis Area Severity Index (PASI score), other disease assessments of involved body surface area (BSA), static physicians global assessment score (sPGA), pruritis and biomarkers associated with the mechanism of disease and AZD0284. Disease activity will be assessed throughout the study as will changes in skin biopsy biomarkers. The study population will be comprised of patients with moderate to severe plaque psoriasis as defined by PASI score, BSA and sPGA.

Following completion of screening assessments and meeting all eligibility criteria, patients will be randomised to receive AZD0284 or placebo for 4 weeks of treatment followed by a 4 week follow up period

03

Conditions studied

  • Plaque Psoriasis Vulgaris

Browse trials for

Keywords

  • Plaque psoriasis
  • PASI
  • BSA
  • sPGA
  • P-VAS
  • IL17A-
  • CCL20
  • PK
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed prior to any study specific procedures.
  • At least 6 months documented history with a diagnosis of moderate to severe plaque psoriasis as defined by the Psoriasis Area and Severity Index (PASI), psoriasis Body Surface Area (BSA) and static Physician Global Assessment (sPGA).

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study, or influence the results or the patient's ability to participate in the study.
  • History and/or presence of tuberculosis, hepatitis, . Other opportunistic infections within 6 months of the study.
  • Clinically significant laboratory abnormalities.
  • Clinically important abnormalities in rhythm, conduction or morphology of the digital (ECG) as considered by the Investigator may interfere with the interpretation of study data.
  • Current treatment or treatment for psoriasis with biological therapies within 6 months of study.
  • Efficacy and safety failure of biologic therapies targeting the IL-17 and IL12/23 pathway at any time.
  • Current treatment or history of treatment for psoriasis with non-biological systemic medications within 4 weeks of Day 1
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
9 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo for AZD0284 oral solution

    Drug: Placebo

  • Experimental
    AZD0284

    AZD0284 oral solution 2.5 mg/mL

    Drug: AZD0284 oral solution 2.5 mg/mL

Interventions

  • DrugAZD0284 oral solution 2.5 mg/mL

    Drug page: AZD-0284

    AZD0284 oral solution 2.5 mg/mL, 100 mg twice daily for for 4 weeks

    Also known as: AZD0284

  • DrugPlacebo

    Placebo for AZD0284 oral solution, twice daily for 4 weeks

06

What researchers measure

Primary outcomes

  1. Reduction from baseline to the end of treatment, in gene expression level of IL-17A and CCL20 relative to placebo.

    Reduction from baseline to the end of treatment, in gene expression level of IL-17A and CCL20 relative to placebo.

    Time frame: 4 weeks

  2. Percent improvement from baseline to the end of treatment in individual Psoriasis Area and Severity Index (PASI) compared to placebo

    Change (percent improvement) in Psoriasis Area and Severity Index score(PASI) compared to placebo

    Time frame: 4 weeks

Secondary outcomes

  1. Proportion of patients achieving 75 % reduction from baseline in PASI score, i.e. PASI 75, at week 4

    Percent patients acheiving a 75% reduction in PASI score

    Time frame: 4 weeks

  2. Proportion of patients achieving 50 % reduction from baseline in PASI score, i.e. PASI 50, at week 4

    Percent patients acheiving a 50% reduction in PASI score

    Time frame: 4 weeks

  3. Reduction in static physician's global assessment (sPGA) score from baseline at week4

    The change in the Static physician's global assessment (sPGA) score will be assessed

    Time frame: 4 weeks

  4. Percent improvement from baseline in involved body surface area (BSA) at week 4

    The percent change in the involved body surface area (BSA) will be assessed

    Time frame: 4 weeks

  5. Reduction in the pruritus visual analogue scale (pVAS) score from baseline, at week 4

    The reduction in the pruritus visual analogue scale (pVAS) score as determined by the patient will be assessed

    Time frame: 4 weeks

  6. Cmax : maximum observed plasma concentration

    Maximum observed plasma concentration (Cmax) will be assessed

    Time frame: 4 weeks

  7. tmax time to reach Cmax

    The time to reach the maximum observed plasma concentration (Cmax) will be assessed

    Time frame: 4 weeks

  8. Cmin minimum observed plasma concentration

    The minimum observed plasma concentration (Cmin) will be assessed

    Time frame: 4 weeks

  9. AE(s) and SAE(s)

    Safety evaluation will include the assessment of adverse and serious adverse events over the course of the study

    Time frame: Approximately 8 weeks throughout the study

07

Study locations

4 sites
  • Research Site
    Aarhus C, 8000, Denmark
  • Research Site
    Hellerup, 2900, Denmark
  • Research Site
    Koebenhavn, 2400, Denmark
  • Research Site
    Odense, 5000, Denmark
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Apr 2018, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2017
First posted
Oct 16, 2017
StartActual
Nov 29, 2017
Primary completionActual
Apr 18, 2018
CompletionActual
Apr 18, 2018
Last update
Apr 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03310320
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 16, 2017
Start date
Nov 29, 2017
Primary completion
Apr 18, 2018
Completion
Apr 18, 2018
Last update
Apr 25, 2019

Study contacts

Ioannis Psallidas, Phd
study director · AstraZeneca R&D, Gothenburg, Sweden

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD-0284

Start the discussion